We are live on ! Find out more
OBIO icon

Orchestra BioMed

56 hedge funds and large institutions have $81.3M invested in Orchestra BioMed in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

6% more capital invested

Capital invested by funds: $77M → $81.3M (+$4.28M)

4% more funds holding

Funds holding: 5456 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.68% less ownership

Funds ownership: 50.65%49.97% (-0.68%)

11% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 18

Holders
56
Holders Change
+2
Holders Change %
+3.7%
% of All Funds
0.75%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
6
Increased
16
Reduced
18
Closed
4
Calls
Puts
Net Calls
Net Calls Change

OBIO Hedge Fund Activity: Q1 2025 in Review

56 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2025, worth a combined $81.3M — up 5.6% from $77M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new OBIO positions and 4 closed out — a net gain of 2 holders — while 16 added to existing stakes and 18 trimmed.

The largest buyer was IFP Advisors, adding an estimated $415K. The largest seller was Boxer Capital Management, exiting entirely with an estimated $953K sold.

  • 56 institutional investors held Orchestra BioMed (OBIO) as of Q1 2025, up from 54 in Q4 2024.
  • Funds reported $81.3M of Orchestra BioMed stock for Q1 2025, up 5.6% quarter-over-quarter.
  • 6 funds opened new Orchestra BioMed positions in Q1 2025 and 4 closed out, a net change of +2 holders.
  • The largest Orchestra BioMed buyer in Q1 2025 was IFP Advisors, an estimated $415K added.
  • The largest Orchestra BioMed seller in Q1 2025 was Boxer Capital Management, an estimated $953K sold.

Based on aggregated 13F filings for Q1 2025.